MX2019010096A - Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa. - Google Patents
Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa.Info
- Publication number
- MX2019010096A MX2019010096A MX2019010096A MX2019010096A MX2019010096A MX 2019010096 A MX2019010096 A MX 2019010096A MX 2019010096 A MX2019010096 A MX 2019010096A MX 2019010096 A MX2019010096 A MX 2019010096A MX 2019010096 A MX2019010096 A MX 2019010096A
- Authority
- MX
- Mexico
- Prior art keywords
- trisubstituted
- benzo
- alkyl
- imidazole derivatives
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
La presente invencion provee derivados de 1, 4, 6-trisustituidos-2-alquil-1Hbenzo[d]imidazol como compuestos inhibidores de dihidroorotato oxigenasa de formula (I), los cuales pueden ser terapeuticamente utiles como inhibidores de DHODH; en los cuales R1 a R3 y 'm' tienen significados dados en la especificacion y sales farmacéuticamente aceptables o estereoisomeros de los mismos que son utiles en el tratamiento y prevencion en enfermedades o trastornos, en particular su uso en enfermedades o trastornos donde existe una ventaja en la inhibicion de DHODH; la presente invencion tambien provee metodos para sintetizar derivados de 1,4,6-trisustituidos-2-alquil-1H-benz o[d]imidazol de formula (I); la presente invención tambien provee formulaciones farmaceuticas que comprenden al menos uno del compuesto inhibidor DHODH de formula (I) junto con un portador farmaceuticamente aceptable, diluyente o excipiente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201741006586 | 2017-02-24 | ||
PCT/EP2018/054602 WO2018154088A1 (en) | 2017-02-24 | 2018-02-23 | 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019010096A true MX2019010096A (es) | 2020-01-09 |
Family
ID=61563366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019010096A MX2019010096A (es) | 2017-02-24 | 2018-02-23 | Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa. |
Country Status (13)
Country | Link |
---|---|
US (1) | US11028054B2 (es) |
EP (1) | EP3585772B1 (es) |
JP (1) | JP7146785B2 (es) |
KR (1) | KR20190120786A (es) |
CN (1) | CN110325514B (es) |
AU (1) | AU2018223982B2 (es) |
BR (1) | BR112019017567A2 (es) |
CA (1) | CA3053068A1 (es) |
EA (1) | EA201991916A1 (es) |
IL (1) | IL268843B (es) |
MA (1) | MA47593A (es) |
MX (1) | MX2019010096A (es) |
WO (1) | WO2018154088A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202104207A (zh) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
EP4136074A1 (en) * | 2020-04-16 | 2023-02-22 | F. Hoffmann-La Roche AG | Indazole derivatives |
JP2023522327A (ja) * | 2020-04-16 | 2023-05-30 | エフ. ホフマン-ラ ロシュ アーゲー | ベンズイミダゾール誘導体 |
EP4136076A1 (en) * | 2020-04-16 | 2023-02-22 | F. Hoffmann-La Roche AG | Biphenyl derivatives |
JP2023521437A (ja) * | 2020-04-16 | 2023-05-24 | エフ. ホフマン-ラ ロシュ アーゲー | ベンズイミダゾール誘導体 |
WO2021209475A1 (en) * | 2020-04-16 | 2021-10-21 | F. Hoffmann-La Roche Ag | Sulfamoylamide derivatives |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
DE59010701D1 (de) | 1990-05-18 | 1997-05-22 | Hoechst Ag | Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung |
GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
JP3979783B2 (ja) | 1997-07-29 | 2007-09-19 | アルコン ラボラトリーズ インコーポレイテッド | ガラクトマンナンポリマー及びホウ酸塩を含む眼科組成物 |
US5904937A (en) | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
AU7622000A (en) * | 1999-10-01 | 2001-05-10 | Institute Of Molecular And Cell Biology | Compounds for the treatment of viral-mediated diseases |
US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
EP1654002B2 (en) | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
ES2882797T3 (es) | 2009-04-02 | 2021-12-02 | Merck Serono Sa | Inhibidores de dihidroorotato deshidrogenasa |
EP3019482B1 (en) * | 2013-02-25 | 2018-08-15 | Aurigene Discovery Technologies Limited | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
-
2018
- 2018-02-23 CN CN201880013651.0A patent/CN110325514B/zh active Active
- 2018-02-23 JP JP2019546029A patent/JP7146785B2/ja active Active
- 2018-02-23 AU AU2018223982A patent/AU2018223982B2/en active Active
- 2018-02-23 MX MX2019010096A patent/MX2019010096A/es unknown
- 2018-02-23 MA MA047593A patent/MA47593A/fr unknown
- 2018-02-23 WO PCT/EP2018/054602 patent/WO2018154088A1/en unknown
- 2018-02-23 CA CA3053068A patent/CA3053068A1/en active Pending
- 2018-02-23 KR KR1020197027373A patent/KR20190120786A/ko unknown
- 2018-02-23 EA EA201991916A patent/EA201991916A1/ru unknown
- 2018-02-23 BR BR112019017567-9A patent/BR112019017567A2/pt not_active Application Discontinuation
- 2018-02-23 EP EP18708631.9A patent/EP3585772B1/en active Active
- 2018-02-23 US US16/488,151 patent/US11028054B2/en active Active
-
2019
- 2019-08-22 IL IL268843A patent/IL268843B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA47593A (fr) | 2020-01-01 |
EP3585772B1 (en) | 2023-10-11 |
IL268843B (en) | 2022-03-01 |
JP7146785B2 (ja) | 2022-10-04 |
EA201991916A1 (ru) | 2020-01-21 |
KR20190120786A (ko) | 2019-10-24 |
WO2018154088A1 (en) | 2018-08-30 |
US11028054B2 (en) | 2021-06-08 |
CA3053068A1 (en) | 2018-08-30 |
IL268843A (en) | 2019-10-31 |
AU2018223982A1 (en) | 2019-08-29 |
AU2018223982B2 (en) | 2022-02-03 |
EP3585772A1 (en) | 2020-01-01 |
BR112019017567A2 (pt) | 2020-03-24 |
JP2020508327A (ja) | 2020-03-19 |
CN110325514A (zh) | 2019-10-11 |
CN110325514B (zh) | 2023-06-13 |
US20200140395A1 (en) | 2020-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019010096A (es) | Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa. | |
WO2014128669A3 (en) | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | |
PH12016501338A1 (en) | Indazole compounds as irak4 inhibitors | |
PH12020500529A1 (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
PH12018502227A1 (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
WO2014106800A3 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
MX2023007192A (es) | Inhibidores de prmt5. | |
WO2014125408A3 (en) | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors | |
MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
MX2020005363A (es) | Compuestos heterociclicos como inhibidores de prmt5. | |
EA033689B9 (ru) | Ингибиторы g12c kras | |
EP3693369A3 (en) | Bromodomain inhibitors | |
MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
MY165902A (en) | Substituted pyridine derivatives as fabi inhibitors | |
CR20230286A (es) | Inhibidores de prmt5 novedosos | |
PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
NZ631388A (en) | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation | |
WO2014072930A3 (en) | Fused pyridine derivatives as antibacterial agents | |
AU2018279669A8 (en) | Carboxylic acid derivative as at AT2R receptor antagonist | |
MX2019012640A (es) | Metodos de uso de derivados de benzotriazoles trisustituidos como inhibidores de dihidroorotato-oxigenasa. | |
ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
IN2014MN02433A (es) |